Updated on 6 July 2026
Designing biomedical devices
Professor at Atatürk University
Erzurum, Türkiye
About
Prostate cancer remains one of the most prevalent malignancies among men worldwide. Current screening strategies based on prostate-specific antigen (PSA) testing suffer from limited specificity, particularly in distinguishing early-stage and clinically significant disease. Consequently, there is a critical need for novel, non-invasive, and highly specific molecular biomarkers to improve early diagnosis and patient stratification.
Circulating microRNAs (miRNAs) have emerged as promising diagnostic candidates due to their remarkable stability in body fluids and their disease-specific expression profiles. Among them, miR-141-3p has been strongly associated with prostate cancer progression, metastatic burden, and treatment response, positioning it as a clinically relevant biomarker for advanced and aggressive disease phenotypes.
Similar opportunities
Project cooperation
AI, Bioinformatics & Multimodal Data Integration Partner for Personalised Medicine
Maria Mastrangelopoulou
Chief Executive Officer at Coremine Vitae
Oslo, Norway
Project cooperation
Kazuhiro Matsuda
CEO & Founder at M Bio Technology Inc.
TOKYO, Japan
Project cooperation
Seeking an eligible European consortium for a healthcare AI challenge and evaluation workstream
- Early
- AI-GenAI /Data/Robotics
- Partner seeks Consortium
Göktuğ Özkan
Internal Medicine Specialist | Clinical AI Safety and Evaluation Researcher at Göktuğ Özkan — Independent Clinical-AI Research
Istanbul, Türkiye